会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明专利
    • 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections
    • NZ626314A
    • 2017-02-24
    • NZ62631413
    • 2013-04-19
    • WOCKHARDT LTD
    • PATIL VIJAYKUMAR JAGDISHWARTADIPARTHI RAVIKUMARDOND BHARATKALE AMOLVELUPILLAI LOGANATHANDEKHANE DEEPAKBIRAJDAR SATISH SHRIMANTSHAIKH MOHAMMAD USMANMAURYA SUSHILKUMARPATEL PIYUSH AMBALALDIXIT PRASADPAWAR MANGESHPATEL MAHESH VITHALBHAIBHAGWAT SACHIN
    • A61K31/439A61K31/4166A61K31/4188A61K31/551A61P31/04C07D471/18
    • Disclosed are 7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide derivatives and prodrugs of Formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof; wherein: R1 is: SO3M, SO2NH2, PO3M, CH2COOM, CF2COOM, CHFCOOM, or CF3; M is hydrogen or a cation; R2 is: hydrogen, (CH2)n-R3, or COOR3; R3 is: hydrogen, optionally substituted alkyl, CN, NR6R7, CONR6R7, NHCONR6R7, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or OR8; and wherein the remaining substituents are as defined herein, and wherein said alkyl is a branched or unbranched saturated acyclic hydrocarbon radical with 1 to 6 carbon atoms; said cycloalkyl is a three to seven member saturated or unsaturated cyclic hydrocarbon radical; said heterocyclyl is a four to seven member cycloalkyl group containing one or more heteroatoms selected from nitrogen, oxygen or sulfur; said aryl is a monocyclic or polycyclic aromatic hydrocarbon containing six to fourteen ring atoms; and said heteroaryl is a monocyclic or polycyclic aromatic hydrocarbon wherein one or more carbon atoms have been replaced with heteroatoms selected from nitrogen, oxygen, or sulfur. Representative compounds include (2S,5R)-N-{ [(2S,4R)-4-trifluoroacetylamino-pyrrolidin-2-yl]methyloxy} -7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide, (2S,5R)-N-{ [(2S)-1-carbamimidoyl-pyrrolidin-2-yl]methyloxy} -7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide, (2S,5R)-7-oxo-N-{ [(2S)-5-oxopyrrolidin-2-yl]methyloxy} -6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide, (2S,5R)-7-oxo-N-{ [(4S)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-oxazol-4-yl]methyloxy} -6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide, (2S,5R)-7-oxo-N-[(2S)-pyrrolidin-2-ylmethyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide, (2S,5R)-N-{ [(2S,4R)-4-hydroxyl-pyrrolidin-2-yl]methyloxy} -7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide, (2S,5R)-N-[(2R)-azetidin-2-ylmethyloxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide, and (2S,5R)-N-hydroxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt. Also disclosed is a pharmaceutical composition comprising a compound as defined above, and optionally further comprising at least one antibacterial agent and/or beta-lactamase inhibitor (such as sulbactam, tazobactam and/or clavulanic acid), for the prevention or treatment of a bacterial infection in a subject, including for the treatment of infection caused by bacteria producing one or more beta-lactamase enzymes.